Dishman’s Clean Sweep! Naroda Facility Clears US FDA Scrutiny
Updated: June 13, 2025 13:21
Image Source: Equity Bulls
Dishman Carbogen Amcis Ltd successfully cleared the US FDA inspection of its Naroda plant without having any observations or issuance of Form 483. This flawless inspection result vindicates the company's strict adherence to regulatory compliance as well as pharmaceutical manufacturing quality standards.
Key Highlights
Inspection Outcome: No Form 483 or observations.
Facility Approved: Naroda unit is compliant with US FDA regulatory requirements.
Global Compliance: Dishman Carbogen Amcis enjoys FDA approvals in different facilities within India, Switzerland, and the Netherlands.
Company Statement: The Dishman management was delighted to have sustained world-class quality and operational excellence.
Industry Impact & Future Outlook
The successful inspection further establishes Dishman Carbogen Amcis' global reputation, ensuring seamless export approvals and business expansion in regulated markets.
Sources: Dishman Carbogen Amcis Latest News, Indian Pharma Post